clinical trial · NCT07116915
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
Guangdong Hengrui Pharmaceutical Co., Ltd·phase1·recruiting·n = 160
COPDHRS-9821 Powder for Inhalation/HRS-9821 inhalation suspensionHRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placeboMoxifloxacin Hydrochloride Tablets
brief summary
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
started
Aug 11, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Feb 27, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol